Institute for Biomedical Sciences, Georgia State University , Atlanta, GA, USA.
Gut Microbes. 2020 May 3;11(3):253-264. doi: 10.1080/19490976.2020.1717719. Epub 2020 Jan 31.
Advances in the understanding of the pathogenesis of type 2 diabetes mellitus (T2D) have revealed a role for gut microbiota dysbiosis in driving this disease. This suggests the possibility that approaches to restore a healthy host-microbiota relationship might be a means of ameliorating T2D. Indeed, recent studies indicate that many currently used treatments for T2D are reported to impact gut microbiota composition. Such changes in gut microbiota may mediate and/or reflect the efficacy of these interventions. This article outlines the rationale for considering the microbiota as a central determent of development of T2D and, moreover, reviews evidence that impacting microbiota might be germane to amelioration of T2D, both in terms of understanding mechanisms that mediate efficacy of exiting T2D therapies and in developing novel treatments for this disorder.
对 2 型糖尿病（T2D）发病机制的认识的进步揭示了肠道微生物群落失调在驱动这种疾病中的作用。这表明，恢复健康的宿主-微生物关系的方法可能是改善 T2D 的一种手段。事实上，最近的研究表明，许多目前用于治疗 T2D 的方法据报道会影响肠道微生物群落的组成。肠道微生物群落的这种变化可能介导和/或反映这些干预措施的疗效。本文概述了将微生物组视为 T2D 发展的一个核心决定因素的基本原理，此外，还回顾了影响微生物组可能与改善 T2D 相关的证据，这既涉及到理解介导现有 T2D 疗法疗效的机制，也涉及到开发治疗这种疾病的新方法。
